Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP10292
- Development stage
- Phase 1
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWP10292 is an orally administered, investigational small-molecule drug candidate developed by Daewoong Pharmaceutical. It was evaluated in completed randomized, double-blind, placebo-controlled single- and multiple-ascending-dose Phase 1 studies in healthy male volunteers, including a multiple-dose study that also evaluated ursodeoxycholic acid as a separate intervention. Public drug-development databases have described DWP10292 as a candidate for fatty liver disease, but its chemical structure, direct molecular target, and mechanism of action have not been publicly disclosed.
- Other names
- DWP-10292DWP10292DWP 10292
Beyond the preview
Go deeper on DWP10292.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP10292.